Level Bio AB (FRA:4MB) Return-on-Tangible-Equity: 0.00% (As of Mar. 2026)


FRA:4MB Level Bio AB FRA:4MB
23 GF Score
Price €0.01
! 4 Warning Signs
View Full Analysis

What is Level Bio AB Return-on-Tangible-Equity?

Level Bio AB FRA:4MB +8.00% 23 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Level Bio AB ranks worse than 97.93% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Level Bio AB's annualized net income for the quarter that ended in Mar. 2026 was €-0.06 Mil. Level Bio AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €-0.01 Mil. Therefore, Level Bio AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for Level Bio AB's Return-on-Tangible-Equity or its related term are showing as below:

FRA:4MB' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -2103.95   Med: -30.81   Max: 67.47
Current: -2103.95

During the past 13 years, Level Bio AB's highest Return-on-Tangible-Equity was 67.47%. The lowest was -2,103.95%. And the median was -30.81%.

FRA:4MB's Return-on-Tangible-Equity is ranked worse than
97.93% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07 vs FRA:4MB: -2103.95

Level Bio AB  (FRA:4MB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Level Bio AB Return-on-Tangible-Equity Related Terms


Level Bio AB Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Level Bio AB's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Level Bio AB Return-on-Tangible-Equity Chart

Level Bio AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.19 -16.96 -105.88 -245.16 -955.88

Level Bio AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -364.07 -1,718.03 -1,000.00 0.00 0.00

FRA:4MB vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison

For the Diagnostics & Research subindustry, Level Bio AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Level Bio AB Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Level Bio AB's Return-on-Tangible-Equity falls into.


FRA:4MB
23GF Score
Level Bio AB FRA:4MB
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Level Bio AB Return-on-Tangible-Equity Calculation

Level Bio AB's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-0.325/( (0.095+-0.027 )/ 2 )
=-0.325/0.034
=-955.88 %

Level Bio AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-0.064/( (-0.027+0.005)/ 2 )
=-0.064/-0.011
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Level Bio AB (FRA:4MB) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Level Bio AB and its competitors. According to the industry distribution chart, Level Bio AB ranks #189 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 97.9%.
Is Level Bio AB's Return-on-Tangible-Equity too high?
Level Bio AB's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Level Bio AB ranks #189 out of 193 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Level Bio AB ranks #189 out of 193 companies for Return-on-Tangible-Equity. This places Level Bio AB in the lower half of its industry. The industry median Return-on-Tangible-Equity is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Level Bio AB and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Bio AB's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Level Bio AB Business Description

Other Exchanges LEVBIO:Sweden
Address Vastra Finnbodavagen 4B, Nacka, Stockholm, SWE, 131 30
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
23GF Score

Get the complete analysis for FRA:4MB

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price